Chronic hepatitis C treatment. Side effects and their management
| Autor: | Ossama A, Shobokshi, Atef O, Tantawe, Bashar M, Al-Kayyal |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
Dose-Response Relationship Drug Maximum Tolerated Dose Saudi Arabia Interferon-alpha Hepatitis C Chronic Interferon alpha-2 Risk Assessment Severity of Illness Index Drug Administration Schedule Recombinant Proteins Treatment Outcome Ribavirin Humans Drug Therapy Combination Female Follow-Up Studies |
| Zdroj: | Saudi medical journal. 24 |
| ISSN: | 0379-5284 |
| Popis: | The current standard of treatment of chronic hepatitis C infection is the combination therapy of pegylated interferon plus ribavirin for 48 weeks for genotype 1 and 4 and 24 weeks for genotype 2 and 3. Side effects such as influenza-like syndrome, gastrointestinal, neuropsychiatric, dermatological and endocrinological symptoms are not uncommon. Laboratory abnormalities such as hematological and biochemical may be frequent. These side effects are compatible with treatment continuation if symptoms are managed carefully. The adverse effects are dose dependent and often reversible. Premature withdrawal rates can be reduced if side effects are identified early. It is, however, pertinent to target treatment to early responders and avoid side effects in patients who have low predictive response to treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|